APOE2 is associated with longevity independent of Alzheimer's disease

  1. Mitsuru Shinohara  Is a corresponding author
  2. Takahisa Kanekiyo
  3. Masaya Tachibana
  4. Aishe Kurti
  5. Motoko Shinohara
  6. Yuan Fu
  7. Jing Zhao
  8. Xianlin Han
  9. Patrick M Sullivan
  10. G William Rebeck
  11. John D Fryer
  12. Michael G Heckman
  13. Guojun Bu  Is a corresponding author
  1. National Center for Geriatrics and Gerontology, Japan
  2. Mayo Clinic, United States
  3. University of Texas Health Science Center at San Antonio, United States
  4. Durham Veterans Health Administration Medical Center's Geriatric Research, United States
  5. Georgetown University Medical Center, United States

Abstract

Although the ε2 allele of apolipoprotein E (APOE2) benefits longevity, its mechanism is not understood. The protective effects of the APOE2 on Alzheimer's disease (AD) risk, particularly through their effects on amyloid or tau accumulation, may confound APOE2 effects on longevity. Herein, we showed that the association between APOE2 and longer lifespan persisted irrespective of AD status, including its neuropathology, by analyzing clinical database as well as animal models. Notably, APOE2 was associated with preserved physical activity during aging, which also associated with lifespan. In animal models, distinct apoE isoform levels, where APOE2 has the highest, were correlated with activity levels, while some forms of cholesterol and triglycerides were associated with apoE and activity levels. These results indicate that APOE2 can contribute to longevity independent of AD. Preserved activity would be an early-observable feature of apoE2-mediated longevity, where higher levels of apoE2 and its-associated lipid metabolism might be involved.

Data availability

All source data files of animal experiments (Figure 2, Figure 4, Supplementary File 1d, and Supplementary File 1f) are included in the manuscript and supporting files. The clinical data are available from NACC (https://www.alz.washington.edu/WEB/researcher_home.html) upon request: distributing any data to a third party, who is not a collaborator or co-authors, is strictly prohibited by NACC.

Article and author information

Author details

  1. Mitsuru Shinohara

    Aging Neurobiology, National Center for Geriatrics and Gerontology, Obu, Japan
    For correspondence
    shinohara@ncgg.go.jp
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3045-7338
  2. Takahisa Kanekiyo

    Neuroscience, Mayo Clinic, Jacksonville, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Masaya Tachibana

    Neuroscience, Mayo Clinic, Jackosonville, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Aishe Kurti

    Neuroscience, Mayo Clinic, Jacksonville, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Motoko Shinohara

    Neuroscience, Mayo Clinic, Jacksonville, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Yuan Fu

    Neuroscience, Mayo Clinic, Jacksonville, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Jing Zhao

    Neuroscience, Mayo Clinic, Jacksonville, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Xianlin Han

    Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Patrick M Sullivan

    Duke University School of Medicine, Durham Veterans Health Administration Medical Center's Geriatric Research, Durham, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. G William Rebeck

    Neuroscience, Georgetown University Medical Center, Washington, DC, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. John D Fryer

    Neuroscience, Mayo Clinic, Jacksonville, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3390-2994
  12. Michael G Heckman

    Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Guojun Bu

    Neuroscience, Mayo Clinic, Jacksonville, United States
    For correspondence
    bu.guojun@mayo.edu
    Competing interests
    The authors declare that no competing interests exist.

Funding

National Institute on Aging (RF1AG057181)

  • Guojun Bu

Naito Foundation

  • Mitsuru Shinohara

BrightFocus Foundation

  • Mitsuru Shinohara

National Center for Geriatrics and Gerontology

  • Mitsuru Shinohara

Hori Sciences and Arts Foundation

  • Mitsuru Shinohara

National Institute on Aging (R37AG027924)

  • Guojun Bu

National Institute on Aging (R01AG046205)

  • Guojun Bu

National Institute on Aging (RF1AG051504)

  • Guojun Bu

National Institute on Aging (P01NS074969)

  • Guojun Bu

National Institute on Aging (P30AG062677)

  • Guojun Bu

Cure Alzheimer's Fund

  • Guojun Bu

National Institute on Aging (R21AG052423)

  • Takahisa Kanekiyo

Japan Heart Foundation

  • Mitsuru Shinohara

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All cohorts examined in this study were generated from homozygous breeding pairs, group housed without enrichment structures in a specific pathogen-free environment in ventilated cages and used in experiments according to the standards established by the Mayo Clinic Institutional Animal Care and Use Committee (IACUC, Protocol# A58312).

Copyright

© 2020, Shinohara et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 6,583
    views
  • 546
    downloads
  • 47
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Mitsuru Shinohara
  2. Takahisa Kanekiyo
  3. Masaya Tachibana
  4. Aishe Kurti
  5. Motoko Shinohara
  6. Yuan Fu
  7. Jing Zhao
  8. Xianlin Han
  9. Patrick M Sullivan
  10. G William Rebeck
  11. John D Fryer
  12. Michael G Heckman
  13. Guojun Bu
(2020)
APOE2 is associated with longevity independent of Alzheimer's disease
eLife 9:e62199.
https://doi.org/10.7554/eLife.62199

Share this article

https://doi.org/10.7554/eLife.62199

Further reading

    1. Medicine
    Gabriel O Heckerman, Eileen Tzng ... Adrienne Mueller
    Research Article

    Background: Several fields have described low reproducibility of scientific research and poor accessibility in research reporting practices. Although previous reports have investigated accessible reporting practices that lead to reproducible research in other fields, to date, no study has explored the extent of accessible and reproducible research practices in cardiovascular science literature.

    Methods: To study accessibility and reproducibility in cardiovascular research reporting, we screened 639 randomly selected articles published in 2019 in three top cardiovascular science publications: Circulation, the European Heart Journal, and the Journal of the American College of Cardiology (JACC). Of those 639 articles, 393 were empirical research articles. We screened each paper for accessible and reproducible research practices using a set of accessibility criteria including protocol, materials, data, and analysis script availability, as well as accessibility of the publication itself. We also quantified the consistency of open research practices within and across cardiovascular study types and journal formats.

    Results: We identified that fewer than 2% of cardiovascular research publications provide sufficient resources (materials, methods, data, and analysis scripts) to fully reproduce their studies. Of the 639 articles screened, 393 were empirical research studies for which reproducibility could be assessed using our protocol, as opposed to commentaries or reviews. After calculating an accessibility score as a measure of the extent to which an article makes its resources available, we also showed that the level of accessibility varies across study types with a score of 0.08 for Case Studies or Case Series and 0.39 for Clinical Trials (p = 5.500E-5) and across journals (0.19 through 0.34, p = 1.230E-2). We further showed that there are significant differences in which study types share which resources.

    Conclusion: Although the degree to which reproducible reporting practices are present in publications varies significantly across journals and study types, current cardiovascular science reports frequently do not provide sufficient materials, protocols, data, or analysis information to reproduce a study. In the future, having higher standards of accessibility mandated by either journals or funding bodies will help increase the reproducibility of cardiovascular research.

    Funding: Authors Gabriel Heckerman, Arely Campos-Melendez, and Chisomaga Ekwueme were supported by an NIH R25 grant from the National Heart, Lung and Blood Institute (R25HL147666). Eileen Tzng was supported by an AHA Institutional Training Award fellowship (18UFEL33960207).

    1. Cell Biology
    2. Medicine
    Pengbo Chen, Bo Li ... Xinfeng Zheng
    Research Article

    Background:

    It has been reported that loss of PCBP2 led to increased reactive oxygen species (ROS) production and accelerated cell aging. Knockdown of PCBP2 in HCT116 cells leads to significant downregulation of fibroblast growth factor 2 (FGF2). Here, we tried to elucidate the intrinsic factors and potential mechanisms of bone marrow mesenchymal stromal cells (BMSCs) aging from the interactions among PCBP2, ROS, and FGF2.

    Methods:

    Unlabeled quantitative proteomics were performed to show differentially expressed proteins in the replicative senescent human bone marrow mesenchymal stromal cells (RS-hBMSCs). ROS and FGF2 were detected in the loss-and-gain cell function experiments of PCBP2. The functional recovery experiments were performed to verify whether PCBP2 regulates cell function through ROS/FGF2-dependent ways.

    Results:

    PCBP2 expression was significantly lower in P10-hBMSCs. Knocking down the expression of PCBP2 inhibited the proliferation while accentuated the apoptosis and cell arrest of RS-hBMSCs. PCBP2 silence could increase the production of ROS. On the contrary, overexpression of PCBP2 increased the viability of both P3-hBMSCs and P10-hBMSCs significantly. Meanwhile, overexpression of PCBP2 led to significantly reduced expression of FGF2. Overexpression of FGF2 significantly offset the effect of PCBP2 overexpression in P10-hBMSCs, leading to decreased cell proliferation, increased apoptosis, and reduced G0/G1 phase ratio of the cells.

    Conclusions:

    This study initially elucidates that PCBP2 as an intrinsic aging factor regulates the replicative senescence of hBMSCs through the ROS-FGF2 signaling axis.

    Funding:

    This study was supported by the National Natural Science Foundation of China (82172474).